Citable filing context

BDX filing events and research context

Server-rendered

BDX's research view summarizes recent SEC filing context, starting with mda_quarterly from May 7, 2026.

BDX filing events and research context
FiledItemContext
May 7, 2026mda_quarterlyBecton, Dickinson and Company (BD) reorganized into four segments—Medical Essentials, Connected Care, BioPharma Systems, and Interventional—following the February 2026 spin-off of its Biosciences and Diagnostic Solutions business. Second-quarter 2026 worldwide revenues increased 5.2% to $4.714 billion, driven by volume growth and favorable foreign currency translation. Key growth drivers included Vascular Access Management, BD Vacutainer, and Advanced Patient Monitoring (specifically HemoSphere Alta and Acumen IQ), alongside double-digit growth in PureWick and GLP-1 delivery products. However, performance was hindered by lower vaccine demand and China’s volume-based procurement (VoBP) programs. Significant regulatory risks persist, including an ongoing FDA Consent Decree regarding Alaris infusion pumps and a Warning Letter for the El Paso facility, which resulted in a voluntary ship hold on ChloraPrep and PurPrep. The company also faces operational headwinds from tariffs and evolving EPA regulations regarding ethylene oxide sterilization. Financially, BD utilized a $4 billion cash distribution from its recent spin-off to fund $2.25 billion in share repurchases and significant debt repayments. Management is currently executing the "Excellence Unleashed" strategy to improve operational efficiency and commercial capabilities amid macroeconomic volatility in the Middle East and China.
Feb 9, 2026mda_quarterlyBecton, Dickinson and Company reported first-quarter fiscal 2026 worldwide revenues of $5.252 billion, a 1.6% increase. The company is transitioning to a new organizational structure and separating its Life Sciences business, combining Biosciences and Diagnostic Solutions with Waters Corporation. Growth was led by the Connected Care segment, driven by BD Rowa pharmacy automation, and the Interventional segment, supported by PureWick and Rotarex Atherectomy System sales. BioPharma Systems saw double-digit U.S. growth in GLP-1 delivery products, though this was offset by lower vaccine demand. Conversely, Medical Essentials and Life Sciences faced headwinds from China’s volume-based procurement (VoBP) programs and reduced governmental research funding. Operating margins were pressured by tariffs and rising labor costs. Significant regulatory risks persist, including an FDA consent decree for Alaris infusion pumps and warning letters regarding Pyxis products and the El Paso facility. Additionally, EPA regulations on ethylene oxide sterilization pose potential operational disruptions. BDX intends to allocate $2 billion from the Waters transaction toward an accelerated share repurchase program, with the remaining proceeds used for debt repayment.
Nov 25, 2025mdaBDX faces significant macroeconomic headwinds, including persistent inflation, currency volatility, and geopolitical instability in Asia and the Middle East. U.S. tariffs and countermeasures are expected to increase operating expenses in fiscal year 2026, compounded by a Section 232 investigation into medical consumables and personal protective equipment. Competitive pressures are intensifying due to the shift of care from acute to non-acute settings and the emergence of alternative therapies, such as oral GLP-1 medications. Pricing is under downward pressure from Group Purchasing Organizations and government initiatives, specifically the CMS Competitive Bidding Program in the U.S. and Volume-Based Procurement in China. A reduction in U.S. government research funding in fiscal year 2025 further impacts the R&D landscape. Operationally, the company is integrating AI and cloud technologies, which increases cybersecurity vulnerability. A critical regulatory risk involves ethylene oxide sterilization; new EPA NESHAP and Interim Registration Review Decision requirements are increasing compliance costs and risking production interruptions. Finally, BDX remains exposed to significant product liability litigation concerning hernia repair implants, vena cava filters, and pelvic organ prolapse products.

Source: SEC EDGAR filing text and events; period May 7, 2026; filed May 7, 2026.

Continue research

Keep researching BDX

Follow same-sector companies and source explainers connected to the research view.

Browse Health Care

Related tickers

LLY
Lilly (Eli)
$1.02T
Health Care
Open company page →
JNJ
Johnson & Johnson
$558.88B
Health Care
Open company page →
ABBV
AbbVie
$393.91B
Health Care
Open company page →
UNH
UnitedHealth Group
$369.32B
Health Care
Open company page →
MRK
Merck & Co.
$295.00B
Health Care
Open company page →
AZN
ASTRAZENECA PLC
$281.75B
Health Care
Open company page →

Related explainers

Understanding 8-K filings

A factual guide to SEC Form 8-K current reports and the material company events they can disclose between quarterly filings.

Read explainer →
Reading a 10-Q

A factual guide to quarterly SEC Form 10-Q reports, how they differ from annual 10-K filings, and what readers can inspect first.

Read explainer →
S-1 and the IPO prospectus

A factual guide to Form S-1 registration statements and the disclosures companies provide before a public offering.

Read explainer →
Reading an SEC 10-K

A factual guide to the core 10-K sections investors use for company context: business description, risk factors, MD&A, financial statements, and segment disclosures.

Read explainer →